Galida - Dual PPAR Agonist for Type 2 Diabetes and Metabolic Syndrome
Key Data:
Drug (brand/generic)
Galida (tesaglitazar) is a dual-acting oral peroxisome proliferator-activated receptor (PPAR) agonist
Company/licensee
AstraZeneca
Therapy class
Dual-acting PPAR agonist
Product description
Oral peroxisome proliferator-activated receptor which targets both PPAR-alpha and PPAr-gamma
Current indication
Treatment of type 2 diabetes/metabolic syndrome
Market sector
Diabetes
Development status
Discontinued
